Drug Target Assessment demo
Every target graded on genetics, expression, biology, tractability, safety and competition, with each grade one click from its evidence. 1:15
What the demo shows
A drug discovery solution for discovery teams that builds graded, cited target reviews in days.
The whole portfolio sits on one evidence matrix: targets down the side, six questions across, every grade opening the claims and source passages behind it. Nine agents plan each assessment, research the six questions in parallel, challenge weak evidence and assemble the document; a weekly evidence watch re-grades a cell when a new study lands. The therapeutic-area lead decides and signs.
Transcript
- Drug Target Assessment builds graded, cited target reviews for drug discovery teams.
- By hand, one target takes four weeks of reading.
- Each target is a row.
- Six questions run across, from genetics to competition.
- Click a grade and its evidence opens.
- Or can two safety is C after one family's fungal infections?
- The matrix keeps watching, rerunning the genetics, safety and competitor searches.
- A new ALS genome-wide study replicates LRRK3.
- Genetics moves from C to B, citation-attached.
- Overall rises to B.
- Dr. Iko Tanaka confirms it for the committee.
- Open the assessment for every cited claim, source passage, and challenge.
- Sign in about five days, not four weeks.
- Built on Botminds: agents, data, screens, and governance on one platform.
Transcribed from the film’s narration. Captions are on the player.